Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus
机构:[1]Peking Union Med Coll Hosp, Key Lab Rheumatol & Clin Immunol, Dept Rheumatol, Minist Educ, Beijing, Peoples R China;[2]Bengbu Med Coll, Affiliated Hosp, Dept Rheumatol, Bengbu, Peoples R China;[3]Guangdong Med Coll, Peoples Hosp Shenzhen 4, Dept Rheumatol, Guangzhou, Guangdong, Peoples R China;[4]Capital Med Univ, Beijing Children Hosp, Dept Rheumatol, Beijing, Peoples R China;临床科室风湿免疫科首都医科大学附属北京儿童医院[5]Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan, Peoples R China;[6]Fourth Mil Med Univ, Xijing Hosp, Dept Clin Immunol & Rheumatol, Xian, Peoples R China;[7]Capital Med Univ, Beijing Tongren Hosp, Dept Rheumatol, Xian, Peoples R China;首都医科大学附属同仁医院[8]Capital Med Univ, Beijing Chao Yang Hosp, Dept Rheumatol, Xian, Peoples R China;内科系统(本部)风湿免疫(本部)北京朝阳医院[9]Anhui Prov Hosp, Dept Rheumatol, Hefei, Peoples R China;[10]Jiangsu Prov Peoples Hosp, Dept Rheumatol, Nanjing, Jiangsu, Peoples R China;江苏省人民医院[11]Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China;[12]Fu Wai Cardiovasc Hosp, Pulm Vasc Ctr, Nanjing, Jiangsu, Peoples R China;[13]Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Rheumatol, Beijing 100730, Peoples R China
Objectives: To estimate the prevalence of pulmonary arterial hypertension (PAH) and risk factors for PAH in patients registered in the Chinese SLE Treatment and Research group (CSTAR) database, the first online registry of Chinese patients with systemic lupus erythematosus (SLE). Methods: A prospective cross-sectional study of patients with SLE was conducted using the CSTAR registry. Resting transthoracic echocardiography was used to estimate pulmonary artery pressure (PAP); PAH was defined as systolic PAP (PASP) >= 40 mmHg. Patients with interstitial lung disease, valvular disease or cardiomyopathy were excluded because of disease influence on PAP. We explored potential risk factors for PAH including patient characteristics, organ involvement, laboratory findings and SLE disease activity. Results: Of 1934 patients with SLE, 74 had PASP with 54.2 +/- 17.1 (40,106) mmHg and were diagnosed with probable PAH. The incidences of lupus nephritis, pleuritis, pericarditis, hypocomplementemia, anti-SSA, and anti-ribonucleoprotein (RNP) were significantly higher in patients with PAH than in those without (p<0.05). SLE disease activity was significantly higher in patients with PAH than in unaffected patients (p<0.05). Multivariate analysis indicated that pericarditis (odds ratio (OR) = 4.248), pleuritis (OR = 3.061) and anti-RNP (OR = 2.559) were independent risk factors for PAH in patients with SLE (p<0.05). Conclusions: The possible prevalence of PAH was 3.8% in Chinese patients with SLE in the CSTAR registry. The significant association of pericarditis, pleuritis and anti-RNP positivity with PAH suggests that higher disease activity and vasculopathy may both contribute to the development of PAH in SLE, which need be treated aggressively to improve prognosis.
基金:
Chinese National Key Technology R&D Program, Ministry of Science and Technology [2008BAI59B02, 2011BAI11B15]; Chinese National High Technology Research and Development Program, Ministry of Science and TechnologyNational High Technology Research and Development Program of China [2012AA02A513]; Research Special Fund for Public Welfare Industry of Health, Ministry of Health [201202004]; National Major Scientific and Technological Special Project for "Significant New Drugs Development" Ministry of Science and Technology [2012ZX09303006-002]
第一作者机构:[1]Peking Union Med Coll Hosp, Key Lab Rheumatol & Clin Immunol, Dept Rheumatol, Minist Educ, Beijing, Peoples R China;
通讯作者:
通讯机构:[1]Peking Union Med Coll Hosp, Key Lab Rheumatol & Clin Immunol, Dept Rheumatol, Minist Educ, Beijing, Peoples R China;[13]Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Rheumatol, Beijing 100730, Peoples R China
推荐引用方式(GB/T 7714):
Li M.,Wang Q.,Zhao J.,et al.Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus[J].LUPUS.2014,23(10):1085-1091.doi:10.1177/0961203314527366.
APA:
Li, M.,Wang, Q.,Zhao, J.,Li, Z.,Ye, Z....&Zeng, X..(2014).Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.LUPUS,23,(10)
MLA:
Li, M.,et al."Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus".LUPUS 23..10(2014):1085-1091